



CORE BRIEF TO MANAGEMENT GROUP MEMBERS

MEETING HELD ON 24 OCTOBER 2019

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

1. Welcome and Introductions

The Chair welcomed members to the meeting.

2. Minutes from Previous Meeting and Action Log

The Minutes from the meetings held on 26 September 2019 were noted.

Members noted that updates to the Action Log were covered in the Managing Director's Report.

3. Draft Integrated Commissioning Plan 2020-23 (ICP)

Members received a presentation and the Draft ICP. The Draft ICP had been shared with Welsh Government who would be providing feedback on 5 November. Members provided feedback and the WHSS Team undertook to circulate a list of actions the following day, which would need to be addressed in advance of the ICP being shared with Joint Committee for consideration at its meeting on 12 November.

4. Report from the Managing Director

Members received the Managing Director's report, which included:

- **WHSSC Assistant Director of Planning** Claire Nelson has been appointed to the substantive role.
- **Perinatal Mental Health - Mother and Baby Unit** Work is continuing with SBUHB in relation to the business case for a new MBU but Welsh Government has asked the WHSS Team to look at an interim solution at an existing facility that could be available from 2020-21, given that a new unit is unlikely to come online before 2021-22.
- **Shropshire and Mid Wales Fertility Centre Service De-Escalation** The service has been taken out of escalation having demonstrated that there were no patients waiting >26 weeks to start fertility treatment and that it is compliant with policy and RTT guidelines.
- **Vulnerable Person's Resettlement Scheme** The WHSS Team has resumed discussions with the Home Office, Welsh Strategic Migration Partnership and Welsh Government about a pilot project,

proposing that WHSSC advises on cases with complex medical conditions to confirm whether they can be treated in Wales.

- **Health Technology Wales and Policy Audits** The WHSS Team is discussing the possibility of a joint project with HTW to audit implementation and compliance of providers to all new WHSSC commissioning policies.
- **Funding Release for Neurosurgery Referral to Treatment** Due to cancellation of a scheduled meeting it had not been possible to obtain details of current demand and how investment was being used to address this. This would be brought back to a future meeting following an SLA meeting with the service.
- **Inherited Metabolic Disorders** A policy was being drafted which would strengthen the processes for the administering and stopping of the high cost therapies.
- **Blueteq** The Cell & Gene Therapy Team at Welsh Blood Service will be working with AWTTC and WHSSC on the phased roll out of the Blueteq package across all health boards and Velindre. The package will enable better management of high cost drugs.
- **Cardiac Surgery Waiting Times** The latest position had been reviewed at a recent joint meeting with CVUHB and SBUHB. Urgent work was required on pathway start dates at SBUHB to enable an understanding of the impact on RTT targets. A collaborative approach had been agreed to consider prioritisation and/or outsourcing of patients from both providers through a risk based process.
- **Vulnerable Groups Portfolio** At the request of Welsh Government WHSSC will be taking forward the commissioning of an All Wales Traumatic Stress Service and support the further development of the Gender Service, Forensic Adolescent Consultation and Treatment Service as well as refugee resettlement. WG will be providing funding for WHSSC to facilitate this for an initial 18 month project.

Members noted the contents of the report.

5. Adult Congenital Heart Disease (CHD)

Members received a paper that provided an update on the investment made in 2015 in Phase 1 Adult CHD.

Members:

- Noted the investment made for the Phase 1 Adult CHD service;
- Noted the benefits of the investments to date;
- Noted the risks around ongoing sustainability of the service; and
- Supported the development of a service specification for CHD.

6. Funding Release – Cochlear Implants and Bone Anchored Hearing Aids (BAHAs)

Members received a paper that requested the release of funding for replacement and upgrade of BAHAs and Cochlear Implants which was included in the ICP 2019-22 prioritisation process to ensure the provision

of a safe, sustainable and effective clinical service for patients in the south Wales region.

Members:

- Noted the information presented within the report; and
- Supported the proposed release of funding for the replacement and upgrade of BAHAs and Cochlear Implants.

7. WHSSC Policy Group Update

Members received a paper on the work of the WHSSC Policy Group and noted the information presented within the report.

8. Integrated Performance Report

Members received a report on the performance of services commissioned by WHSSC for August 2019 and noted the services in escalation and actions being undertaken to address areas of non-compliance.

9. Finance Report 2019-20 Month 6

Members received a report that set out the financial position for WHSSC for the sixth month of 2019-20, following a full review and release of reserves, being an under spend of £2,048k and forecast underspend of £3,862k for the full year.

10. Any Other Business

- **CTMUHB Business Case for PCI** It was reported that the PCI Business Case had been approved by the CTMUHB Board and would now be forwarded to WHSSC.
- **PET Commissioning** It was noted that while BCUHB has commenced an engagement exercise on medical physics for north Wales, PET commissioning is an all Wales process led by WHSSC.

